Aspirin resistance refers to less than expected suppression of thromboxane A2 production
by aspirin and has been reported to be independently associated with an increased risk of …

Aspirin is an effective antiplatelet agent with proven benefit in the prevention of
atherothrombotic complications of cardiovascular disease. The antithrombotic effects of …

Conclusions The correct treatment, if any, of aspirin 'resistance'is unknown. No published
studies address the clinical effectiveness of altering therapy based on a laboratory finding of …

Aspirin reduces major atherothrombotic events across a wide spectrum of patients with
atherosclerotic disease. The occurrence of ischemic events despite of aspirin treatment is a …

There is a perception that up to 40% of aspirin users may be resistant to aspirin, and given
the widespread use of this drug to reduce cardiovascular risk, could this mean that large …

Aspirin (acetylsalicylic acid) is one of the main therapeutic medications used in the
prevention of thromboembolic vascular events. Aspirin exhibits its antiplatelet action by …

Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A 2
and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance …

Acetylsalicylic acid (aspirin) has been shown to irreversibly interfere with platelet function,
an effect that is associated with a reduction in morbid and mortal arterial thrombotic events in …

Aspirin is the most commonly used therapeutic agent in prevention of vascular ischemic
events. Aspirin exerts its antithrombotic effect primarily by interfering with the biosynthesis of …

Treatment failures occur with any drug and aspirin is no exception. Evidence is growing to
indicate that there are subpopulations that do not respond to antithrombotic action of aspirin …